Neural computing in cancer drug development: predicting mechanism of action - PubMed (original) (raw)
. 1992 Oct 16;258(5081):447-51.
doi: 10.1126/science.1411538.
Affiliations
- PMID: 1411538
- DOI: 10.1126/science.1411538
Neural computing in cancer drug development: predicting mechanism of action
J N Weinstein et al. Science. 1992.
Abstract
Described here are neural networks capable of predicting a drug's mechanism of action from its pattern of activity against a panel of 60 malignant cell lines in the National Cancer Institute's drug screening program. Given six possible classes of mechanism, the network misses the correct category for only 12 out of 141 agents (8.5 percent), whereas linear discriminant analysis, a standard statistical technique, misses 20 out of 141 (14.2 percent). The success of the neural net indicates several things. (i) The cell line response patterns are rich in information about mechanism. (ii) Appropriately designed neural networks can make effective use of that information. (iii) Trained networks can be used to classify prospectively the more than 10,000 agents per year tested by the screening program. Related networks, in combination with classical statistical tools, will help in a variety of ways to move new anticancer agents through the pipeline from in vitro studies to clinical application.
Similar articles
- Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's Drug Discovery Program for Cancer and AIDS.
Weinstein JN, Myers T, Buolamwini J, Raghavan K, van Osdol W, Licht J, Viswanadhan VN, Kohn KW, Rubinstein LV, Koutsoukos AD, et al. Weinstein JN, et al. Stem Cells. 1994 Jan;12(1):13-22. doi: 10.1002/stem.5530120106. Stem Cells. 1994. PMID: 8142917 - Discrimination techniques applied to the NCI in vitro anti-tumour drug screen: predicting biochemical mechanism of action.
Koutsoukos AD, Rubinstein LV, Faraggi D, Simon RM, Kalyandrug S, Weinstein JN, Kohn KW, Paull KD. Koutsoukos AD, et al. Stat Med. 1994 Mar 15-Apr 15;13(5-7):719-30. doi: 10.1002/sim.4780130532. Stat Med. 1994. PMID: 8023045 - Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action.
Huang R, Wallqvist A, Thanki N, Covell DG. Huang R, et al. Pharmacogenomics J. 2005;5(6):381-99. doi: 10.1038/sj.tpj.6500331. Pharmacogenomics J. 2005. PMID: 16103895 - Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics.
Yamori T. Yamori T. Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S74-9. doi: 10.1007/s00280-003-0649-1. Epub 2003 Jun 18. Cancer Chemother Pharmacol. 2003. PMID: 12819939 Review. - Screening with COMPARE analysis for telomerase inhibitors.
Naasani I, Yamori T, Tsuruo T. Naasani I, et al. Methods Mol Biol. 2002;191:197-207. doi: 10.1385/1-59259-189-2:197. Methods Mol Biol. 2002. PMID: 11951607 Review. No abstract available.
Cited by
- The Artificial Intelligence-Powered New Era in Pharmaceutical Research and Development: A Review.
Suriyaamporn P, Pamornpathomkul B, Patrojanasophon P, Ngawhirunpat T, Rojanarata T, Opanasopit P. Suriyaamporn P, et al. AAPS PharmSciTech. 2024 Aug 15;25(6):188. doi: 10.1208/s12249-024-02901-y. AAPS PharmSciTech. 2024. PMID: 39147952 Review. - Cephalometric Analysis in Orthodontics Using Artificial Intelligence-A Comprehensive Review.
Subramanian AK, Chen Y, Almalki A, Sivamurthy G, Kafle D. Subramanian AK, et al. Biomed Res Int. 2022 Jun 16;2022:1880113. doi: 10.1155/2022/1880113. eCollection 2022. Biomed Res Int. 2022. PMID: 35757486 Free PMC article. Review. - Towards the Interpretability of Machine Learning Predictions for Medical Applications Targeting Personalised Therapies: A Cancer Case Survey.
Banegas-Luna AJ, Peña-García J, Iftene A, Guadagni F, Ferroni P, Scarpato N, Zanzotto FM, Bueno-Crespo A, Pérez-Sánchez H. Banegas-Luna AJ, et al. Int J Mol Sci. 2021 Apr 22;22(9):4394. doi: 10.3390/ijms22094394. Int J Mol Sci. 2021. PMID: 33922356 Free PMC article. Review. - QSAR-derived affinity fingerprints (part 1): fingerprint construction and modeling performance for similarity searching, bioactivity classification and scaffold hopping.
Škuta C, Cortés-Ciriano I, Dehaen W, Kříž P, van Westen GJP, Tetko IV, Bender A, Svozil D. Škuta C, et al. J Cheminform. 2020 May 29;12(1):39. doi: 10.1186/s13321-020-00443-6. J Cheminform. 2020. PMID: 33431038 Free PMC article. - Identifying new topoisomerase II poison scaffolds by combining publicly available toxicity data and 2D/3D-based virtual screening.
Lovrics A, Pape VFS, Szisz D, Kalászi A, Heffeter P, Magyar C, Szakács G. Lovrics A, et al. J Cheminform. 2019 Nov 9;11(1):67. doi: 10.1186/s13321-019-0390-3. J Cheminform. 2019. PMID: 33430961 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources